VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Drop in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 87,870 shares, a decline of 88.7% from the January 29th total of 774,911 shares. Based on an average trading volume of 394,842 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.5% of the company’s shares are sold short. Approximately 3.5% of the company’s shares are sold short. Based on an average trading volume of 394,842 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors and hedge funds.

VivoSim Labs Stock Performance

VivoSim Labs stock traded up $0.11 during midday trading on Wednesday, hitting $2.05. 105,872 shares of the company’s stock were exchanged, compared to its average volume of 4,915,803. The company has a market cap of $5.35 million, a PE ratio of -0.97 and a beta of 1.21. The firm has a 50-day moving average of $2.03 and a two-hundred day moving average of $2.37. VivoSim Labs has a 12 month low of $1.41 and a 12 month high of $18.60.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings results on Wednesday, February 11th. The company reported ($1.03) EPS for the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%. The business had revenue of $0.03 million during the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.